Search This Blog

Friday, March 7, 2025

Mexico's Ramirez de la O steps down as finance minister, sources say

 Mexican Finance Minister Rogelio Ramirez de la O has stepped down, two sources familiar with the matter said on Friday, having been appointed by the country's previous president Andres Manuel Lopez Obrador.

Edgar Amador Zamora, who currently is deputy finance minister, has been tapped to replace Ramirez de la O, the two sources said, speaking on the condition of anonymity because the information was private.

In June of last year, Ramirez de la O sought to reassure investors and said he would stay in his current role with the incoming government of President Claudia Sheinbaum to reduce public debt and maintain financial discipline.

It was not clear why he decided to step down. The finance ministry did not immediately respond to a request for further comment.

The reshuffle in the finance ministry, which was first reported by local media, comes as Latin America's second-largest economy is facing possible tariffs from its northern neighbor and most important trade partner.

On Thursday, U.S. President Donald Trump suspended tariffs of 25% he had imposed this week on most goods from Mexico and Canada, the latest twist in a fluctuating trade policy that has whipsawed markets and fanned worries about inflation and growth.

The exemptions expire on April 2, when Trump has threatened to impose a global regime of reciprocal tariffs on all of the country's trading partners.

https://www.usnews.com/news/world/articles/2025-03-07/mexicos-finance-minister-ramirez-de-la-o-steps-down-sources-say

CDC Says Risk For Widespread Measles In U.S. Remains Low

'The risk for widespread measles in the United States remains low due to robust U.S. immunization and surveillance programs and outbreak response capacity supported by federal, state, tribal, local, and territorial health partners.'

Novo’s Studies of GLP-1s for Addiction Limited to Ongoing Phase II

 

Despite comments made by a Novo Nordisk official this week, the company confirmed to BioSpace that it has no additional clinical trials of its GLP-1 drugs in addiction beyond a Phase II trial testing semaglutide and two other drugs with alcohol use as a secondary endpoint.

Thursday, Reuters reported that Martin Holst Lange, head of development at Novo, had told an online conference on Thursday that his company plans to investigate how its GLP-1 medicines can help people with addiction.

However, in response to questions from Biospace, a Novo spokesperson said that Lange was referring to already ongoing work studying semaglutide on liver damage and alcohol use, and that the company has no plans to study the drug in broader addiction indications.

“There is nothing else in terms of clinical trials we have ongoing in this space at the moment,” the spokesperson said in an email.

Novo currently markets its GLP-1 treatments, which both contain the active ingredient semaglutide, as Wegovy for weight loss and Ozempic for type II diabetes. However, there is an early but growing interest in the potential of these molecules to treat substance abuse disorders, their related effects and a bevy of other conditions.

The Phase II trial, launched in May 2024 and currently recruiting globally, is studying the effectiveness of semaglutide and two other drugs—cagrilintide, an amylin analogue, and NNC0194-0499, an FGF21 analog—used alone or in combination, in patients with alcoholic liver disease. Treatment of liver damage is that trial’s primary endpoint and alcohol consumption is a secondary endpoint.

Three months ago, Novo’s biggest competitor Eli Lilly shared its plans to study its own GLP-1 medicines in alcohol and drug abuse. While Lilly has not officially announced any trials, CEO David Ricks said at an event in December that the company would begin large studies of its obesity drugs in alcohol and drug abuse next year, according to Endpoints News.

Currently, pharmaceutical treatment for addiction and substance-use disorders is limited, with most treatments aimed at avoiding overdoses or reducing withdrawal symptoms. But the industry is attempting inroads, with psychedelic therapies like LSD and ketamine drawing attention from researchers and biopharma companies. Another area of interest is in vaccination. In 2021 the NIH awarded a $25 million grant to scientists at Boston Children’s Hospital to study a vaccine against opioids. The hope is that the vaccine would generate antibodies to prevent the molecules from crossing into the brain.

Novo is making progress with GLP-1 on another neurological front. In October 2024, semaglutide was linked with a significant reduction—40% to 70%—in the risk of Alzheimer’s disease in a real-world study of patients with type 2 diabetes. Novo is running two Phase III trials, EVOKE and EVOKE Plus, formally testing semaglutide in patients with Alzheimer’s. Those trials are expected to read out in September of this year.

https://www.biospace.com/drug-development/novos-studies-of-glp-1s-for-addiction-limited-to-ongoing-phase-ii

FDA clears revision knee implant from Zimmer Biomet

 Zimmer Biomet (NYSE: ZBH)

 announced today that it received FDA 510(k) clearance for its Persona Revision SoluTion Femur.

The revision knee implant component — part of the comprehensive Persona Revision Knee System — offers an alternative for patients with sensitivities to certain metals.  It leverages a proprietary surface-hardening treatment designed to enhance wear performance. It delivers surgeons an array of anatomic components, including tibial and femoral cones with various stem choices to address zonal fixation.

Warsaw, Indiana-based Zimmer Biomet made its implant solely from a proprietary Tivanium (Ti-6Al-4V) alloy. The alloy has more than 17 years of clinical use backing it. Treated with the Ti-Nidium surface-hardening process, the alloy strengthens to demonstrate hardness comparable to that of metal implants. However, it delivers enhanced wear performance with resistance to particle release.

Zimmer Biomet offers the new revision femur in standard and plus sizes to address flexion instability and soft tissue balancing. It also minimizes implant overhang.

The company plans to make the Persona Revision SoluTion Femur commercially available in the U.S. in the third quarter of 2025.

“We are pleased to expand our proprietary surface-hardening technology into the revision knee space with FDA clearance of the Persona Revision SoluTion Femur, the first metal alternative option for those with certain metal sensitivities,” said Joe Urban, president, Knees at Zimmer Biomet. “We are proud to offer a total revision knee construct with no deliberate addition of the most common metal allergens (Nickel, Cobalt, & Chromium). Metal sensitivity is one of the potential causes of revision procedures, and the Persona Revision SoluTion Femur is yet another innovation that delivers on our commitment to solve the most meaningful challenges in musculoskeletal health.”

https://www.massdevice.com/fda-clears-revision-knee-implant-zimmer-biomet/

CDC Plans Large Study on Autism and Vaccines, Report Says

 The CDC is planning a large study looking into potential connections between vaccines and autism, two sources told Reuters

opens in a new tab or window, despite significant research showing vaccines and autism are not linked.

The move comes during one of the largest measles outbreaks in the past decade, with two deaths in Texas and New Mexico. In Texas, 198 cases have been identifiedopens in a new tab or window since late January, and 23 patients have been hospitalized.

It's unclear whether HHS Secretary Robert F. Kennedy Jr., who has long promoted anti-vaccine views, is involved in the planned CDC study or how it would be carried out, Reuters said.

Kennedy has misstated key factsopens in a new tab or window about the current measles outbreak and has promoted vitamin Aopens in a new tab or window as a measles treatment instead of emphasizing vaccines. He recently published an opinion pieceopens in a new tab or window for Fox News that said vaccination was a personal choice and urged parents to consult with their physicians.

Since at least 2014, President Donald Trump also has floated a theoryopens in a new tab or window that vaccines are behind the rise in autism cases, but no evidence indicates this is true.

Vaccines were first blamed in 1998, when Andrew Wakefield, MBBS, formerly of the Royal Free Hospital and School of Medicine in London, published a now-retracted paperopens in a new tab or window in The Lancet stating that 12 children had intestinal abnormalities after receiving the measles, mumps, and rubella (MMR) vaccination. For eight of the 12 children, parents linked the onset of behavioral symptoms to the vaccine.

Wakefield and co-authors hypothesized that intestinal inflammation after the MMR vaccine released gut proteins that eventually migrated to the brain, causing damage that was reflected in autism symptoms.

"The Wakefield study was flawed because nothing was studied," Paul Offit, MD, of the Children's Hospital of Philadelphia, told MedPage Today in an interview earlier this year.

"It was merely a report of eight children who had developed signs and symptoms of autism within a month of receiving the MMR vaccine. There was not a control group," he emphasized. "Therefore, there was no way of knowing whether autism was occurring at a level greater than would be expected by chance alone."

In 1999, another group of London-based researchers found no epidemiological evidence for a causal association between autism and the MMR vaccine. That conclusion was played out repeatedly in studies published in subsequent years. One of the largest was a retrospective analysis of more than 537,000 childrenopens in a new tab or window in Denmark, which showed the risk of autism diagnosis was similar between those who received the MMR vaccine and those who did not.

Other hypotheses linking autism and vaccines that have been debunkedopens in a new tab or window centered around thimerosal, a preservative used in some multidose vials of vaccines, and arguments claiming that administering multiple vaccines at once may weaken the immune system. All vaccines routinely recommended for children ages 6 years and younger in the U.S. are available in formulations without thimerosalopens in a new tab or window, according to the FDA.

In the past two decades, autism diagnoses among childrenopens in a new tab or window in the U.S. have jumped fourfold, according to CDC data. Several factors may have fueledopens in a new tab or window the rising prevalence numbers, including a changing definition of autism, better awareness and ascertainment, and increased screening and surveillance. While the cause of autism is unknown, some research suggests environmental factors may interact with genetic predisposition to raise autism risk.

The CDC and HHS were not immediately available for comment, according to Reuters.

https://www.medpagetoday.com/neurology/autism/114545

Trump Plans to Restrict Loan Forgiveness for Non-Profit Workers

 


President Donald Trump plans to sign an executive order that will restrict eligibility for a government-run student loan forgiveness program, targeting individuals whose work for non-profits clashes with the administration’s immigration policies.

White House Staff Secretary Will Scharf said that Trump plans to sign a directive Friday that will rescind student loan forgiveness for people who work for non-governmental organizations engaged in what he called “improper activities” tied to illegal immigration and terrorist organizations.

https://www.bloomberg.com/news/articles/2025-03-07/trump-plans-to-restrict-loan-forgiveness-for-non-profit-workers

Jefferies Adjusts Viatris Price Target to $13 From $15, Maintains Buy Rating

 Viatris has an average rating of Hold and mean price target of $11.17, according to analysts polled by FactSet. Price: 9.59, Change: +0.08,

https://www.marketscreener.com/quote/stock/VIATRIS-INC-115117632/news/Jefferies-Adjusts-Viatris-Price-Target-to-13-From-15-Maintains-Buy-Rating-49273594/